Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.77−0.01 (-0.10%)
Close on Nov 18, 2026Market cap $1.37BP/E –Yield –
Intellia Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Intellia Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $59.51M, up 12.6% year over year. For fiscal 2025 it was $67.67M, up 16.9% from the year before. The highest annual figure on record is $67.67M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.67M | +16.9% |
| FY2024 | Dec 31, 2024 | $57.88M | +59.6% |
| FY2023 | Dec 31, 2023 | $36.28M | -30.4% |
| FY2022 | Dec 31, 2022 | $52.12M | +57.7% |
| FY2021 | Dec 31, 2021 | $33.05M | -43.0% |
| FY2020 | Dec 31, 2020 | $57.99M | +34.5% |
| FY2019 | Dec 31, 2019 | $43.10M | +41.6% |
| FY2018 | Dec 31, 2018 | $30.43M | +16.5% |
| FY2017 | Dec 31, 2017 | $26.12M | +58.5% |
| FY2016 | Dec 31, 2016 | $16.48M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.66M | -46.2% |
| Q1 FY2026 | Mar 31, 2026 | $15.05M | -9.5% |
| Q4 FY2025 | Dec 31, 2025 | $23.02M | +78.8% |
| Q3 FY2025 | Sep 30, 2025 | $13.78M | +51.3% |
| Q2 FY2025 | Jun 30, 2025 | $14.25M | +104.8% |
| Q1 FY2025 | Mar 31, 2025 | $16.63M | -42.5% |
| Q4 FY2024 | Dec 31, 2024 | $12.87M | +7.4% |
| Q3 FY2024 | Sep 30, 2024 | $9.11M | -33.0% |
| Q2 FY2024 | Jun 30, 2024 | $6.96M | -44.8% |
| Q1 FY2024 | Mar 31, 2024 | $28.94M | +113.2% |
| Q3 FY2023 | Sep 30, 2023 | $11.99M | -9.6% |
| Q2 FY2023 | Jun 30, 2023 | $13.59M | -3.1% |
| Q1 FY2023 | Mar 31, 2023 | $12.61M | +12.0% |
| Q4 FY2022 | Dec 31, 2022 | $13.57M | +5.6% |
| Q3 FY2022 | Sep 30, 2022 | $13.27M | +84.1% |
| Q2 FY2022 | Jun 30, 2022 | $14.03M | +114.2% |
| Q1 FY2022 | Mar 31, 2022 | $11.25M | +74.6% |
| Q4 FY2021 | Dec 31, 2021 | $12.85M | +94.9% |
| Q3 FY2021 | Sep 30, 2021 | $7.20M | -67.6% |
| Q2 FY2021 | Jun 30, 2021 | $6.55M | -59.7% |
| Q1 FY2021 | Mar 31, 2021 | $6.45M | -50.1% |
| Q4 FY2020 | Dec 31, 2020 | $6.60M | -39.7% |
| Q3 FY2020 | Sep 30, 2020 | $22.22M | +109.3% |
| Q2 FY2020 | Jun 30, 2020 | $16.26M | +46.3% |
| Q1 FY2020 | Mar 31, 2020 | $12.92M | +23.8% |
| Q4 FY2019 | Dec 31, 2019 | $10.94M | +38.8% |
| Q3 FY2019 | Sep 30, 2019 | $10.62M | +43.3% |
| Q2 FY2019 | Jun 30, 2019 | $11.12M | +44.8% |
| Q1 FY2019 | Mar 31, 2019 | $10.43M | +39.7% |
| Q4 FY2018 | Dec 31, 2018 | $7.88M | +18.2% |
| Q3 FY2018 | Sep 30, 2018 | $7.41M | +1.2% |
| Q2 FY2018 | Jun 30, 2018 | $7.68M | +29.7% |
| Q1 FY2018 | Mar 31, 2018 | $7.47M | +20.2% |
| Q4 FY2017 | Dec 31, 2017 | $6.67M | – |
| Q3 FY2017 | Sep 30, 2017 | $7.32M | – |
| Q2 FY2017 | Jun 30, 2017 | $5.92M | – |
| Q1 FY2017 | Mar 31, 2017 | $6.22M | – |
See a number that looks wrong?